Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. … LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway.

  2. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia.

  3. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors. … Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing.

  4. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.

    Categories: Drugs for Treatment of Bone DiseasesProducts: Pamidronate Disodium for Injection, MENEDRON-L 15 MG IV ENJEKSİYONLUK LİYOFİLİZE TOZ İÇEREN FLAKON (4 FLAKON)
  5. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Pegvaliase-pqpz, or PEGylated pegvaliase, is used as a novel enzyme substitution therapy and is marketed as Palynziq for subcutaneous injection. … to 3690 µmol/L [A33286].

  6. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  7. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  8. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  9. Drug

    Desirudin

    go.drugbank.com/drugs/DB11095
    ApprovedWithdrawn

    It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. … Desirudin is a direct inhibitor of human thrombin.

  10. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840). … In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713].

    Categories: Experimental Unapproved Treatments for COVID-19